On-Demand Webinar: Go with the Flow: Advancing Cell and Gene Therapy with Flow Cytometry
Overview:
The treatment of a broad range of diseases such as some cancers, immune and cardiac disorders, is being pioneered using cell and/or gene therapies.
Cell therapy is a broad term, where various cell populations, often stem cells, are introduced into a patient.
In gene therapy, clinicians send a healthy copy of a gene into patient cells. It is anticipated that the healthy gene will replace a mutated gene or inactivate a mutated gene.
Both gene and cell therapies can be a challenge to manufacture. The challenges include scaling up cell production, harvesting and washing cells without a loss of viability, ensuring the longevity and selectivity of chimeric antigen receptor (CAR)-T cells, and also effectively delivering a therapy to a patient.
Flow cytometry is a key technique in the development and manufacture of gene and cell therapies. It can rapidly identify cell defects, monitor the cell cycle, assess cell function and viability and confirm if a therapeutic genetic modification is functioning in a cell.
This webinar’s speakers discuss recent advances in gene and cell therapy fields, and the technologies which are rendering the next generation of these treatments a reality.
The webinar includes discussion on:
- The latest techniques and strategies used in the development and manufacture of gene and cell therapies
- Current applications for flow cytometry in cell and gene therapy
- Flow cytometry’s benefits in cell and gene therapy, plus new applications on the horizon
Webinar Speakers
Marina Cavazzana, M.D., Ph.D.
Necker-Enfants Malades Hospital
Paris, France
Marina Cavazzana’s main research and clinical interests are the development of the hematopoietic immune system and cell and gene therapy for inherited and acquired disease of the hematopoietic system. Her group studies ways to improve the clinical results of hematopoietic stem cell transplantation, crossing HLA-barriers, and the differentiation of mouse and human stem cells into lymphocyte lineages.
She has initiated several clinical trials based on the use of ex vivo gene-modified hematopoietic stem cells to treat patients with inherited disorders, the preliminary clinical results of which are encouraging.
Her work was rewarded by the American Society of Hematology (Award on Clinical Research in Gene Therapy in 1999) and by the French Academy of Sciences (Special Medical Award in 2000 and Jean-Pierre Lecocq Grand Prize for gene therapy in 2004). She was awarded the title of Officier de l'Ordre National de la Légion d'honneur in 2011, and given the 2012 Irène Joliot Curie Prize “Woman Scientist of the Year” by the French Academy of Sciences and French Ministry of Higher Education and Research.
She was also awarded the French National Academy of Medicine Prize in 2016 and the 2017 Ernest Beutler Lecture and Prize for Clinical Science (American Society of Hematology). She was elected an international member of the National Academy of Medicine in 2019.
Sebastian Kobold, M.D., Ph.D.
Hospital of the Ludwig-Maximilians-Universität München
Munich, Germany
Sebastian Kobold, M.D., Ph.D., is a professor of experimental immuno-oncology, head of the immunopharmacology group, and deputy director of the division of clinical pharmacology at the University Hospital of Munich.
He has received, amongst many other awards, the 2022 cancer research prize of the Berlin-Brandenburg Academy of Sciences.
Focusing on tumor immunology, Dr. Kobold is especially interested in developing and testing novel strategies to treat cancer using the immune system. His goal is to translate his findings into clinical applications to improve therapies for cancer patients.
